The almost 50-year odyssey of cardiac imaging in hypertrophic cardiomyopathy (HCM), revisited and described here, has been remarkable, particularly when viewed in the timeline of advances that occurred during a single generation of investigators. At each step along the way, from M-mode to 2-dimensional echocardiography to Doppler imaging, and finally over the last 10 years with the emergence of high-resolution tomographic cardiac magnetic resonance (CMR), evolution of the images generated by each new technology constituted a paradigm change over what was previously available. Together, these advances have transformed the noninvasive diagnosis and management of HCM in a number of important clinical respects. These changes include a more complete definition of the phenotype, resulting in more reliable clinical identification of patients and family members, defining mechanisms (and magnitude) of left ventricular outflow obstruction, and novel myocardial tissue characterization (including in vivo detection of fibrosis/scarring); notably, these advances afford more precise recognition of at-risk patients who are potential candidates for life-saving primary prevention defibrillator therapy. This evolution in imaging as applied to HCM has indelibly changed cardiovascular practice for this morphologically and clinically complex genetic disease. (J Am Coll Cardiol Img 2016;9:858-72) 
S
ince the initial description of hypertrophic cardiomyopathy (HCM) >50 years ago, most of our understanding of this complex and heterogeneous genetic heart disease has resulted from insights gained through advances in cardiovascular imaging techniques. Indeed, perhaps no other heart disease has been so uniquely suited to noninvasive imaging as HCM (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) . In many respects, the development of cardiac imaging from M-mode echocardiography to cardiac magnetic resonance (CMR) transpiring over several decades has paralleled the evolving understanding of this clinically and morphologically diverse disease (Figures 1 and 2 ). Therefore, in this comprehensive historical review, we revisit the development of imaging technology to assess its impact on the diagnosis and management of HCM (10) .
THE BEGINNING
In the early 1960s, Dr. Harvey Feigenbaum (Indianapolis, Indiana) was largely responsible for the clinical adaptation of cardiac ultrasound (which he termed "echocardiography") (11) (12) (13) (14) (15) , due to his vision, energy and focus, and fervent belief in this new technology. Dr. Feigenbaum formulated a worldwide initiative that included publications, workshops, national/international conferences, a comprehensive textbook spanning 45 years, the first commercially available sector scanner, and a cadre of trainees who carried forth a new message to a skeptical establishment.
Early investigations from the Feigenbaum laboratory reported the capability of measuring left ventricular (LV) wall thickness and cavity dimensions, and recognition of the ventricular septum (12, (14) (15) (16) .
These observations and those of other investigators (17, 18) were instrumental in promoting the imaging revolution for cardiac diseases (prominently including HCM).
EARLY HISTORICAL PERSPECTIVES ON CARDIAC/HCM DIAGNOSES
The initial contemporary morphologic description of HCM was recorded in 1958 by Dr. Donald Teare, the Coroner of London (19) . In 8 young patients who had Figure 1 .
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Imaging in Hypertrophic Cardiomyopathy of the many LVH patterns within the broad HCM disease spectrum (4), followed by an expanded analysis of 600 patients (56) . This research created an appreciation for HCM phenotypic heterogeneity and a morphologic classification (4) that is still used (57).
Specifically, the continuous short-axis scan showed that although LVH is often distributed diffusely, it may also reside segmentally in isolated sites remote from the anterior septum (4, 5, 56) (Figure 3 ), as first underscored in a 1981 2DE paper describing "unusual locations of LVH undetected by M-mode" (e.g., posterior septum, anterolateral free wall, and apex [54] ). Maron and Maron
occasionally in adulthood (66, 67) . With 2DE visualization of the LV chamber, family screening became far more reliable than was possible with M-mode alone using the septal-free wall ratio (68) . Figures 1 and 2 . mutations among these genes, many of which are pathogenic for HCM (92 (or outcome) in HCM. Conversely, these observations support the notion that HCM is not composed of many unrelated conditions but is rather a unified (albeit diverse) disease of the sarcomere.
FUTURE DIRECTIONS
Due to the remarkable advances in echocardiography and CMR imaging over 5 decades, appreciation for the vast morphologic expression of HCM can be considered highly advanced, at least in terms of clinical diagnosis and investigation. However, the overall HCM imaging story is likely far from over.
We can speculate that the future imaging era for HCM will be focused on emerging techniques defining the myocardial substrate with greater precision, including insights into heart muscle metabolism and biochemistry, as well as more robust tissue characterization, all of which would have been unimaginable to the early pioneers of M-mode and 2DE. 
